# Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

> **NCT07100080** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 596 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Iza-bren
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT07100080
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2028-09-15
- **Final completion:** 2031-05-15
- **Target enrollment:** 596 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100080, "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07100080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*